However, a meta-analysis reported a higher incidence of urinary tract infections (UTIs) among patients receiving SGLT2 inhibitors compared with those administered a placebo (odds ratio [OR]: 1.34, 95% confidence interval [CI]: 1.03-1.74). Here, SLC5A2 is linked to urinary tract infection.